HSD17B7

Across TCGA pan-cancer cohorts, HSD17B7 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of HSD17B7’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HSD17B7 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types HSD17B7 is over-expressed in tumor.

CCRCC, COAD, and LUAD are the cancer types where HSD17B7 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HSD17B7 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	+0.492	<.001	10	view →
COAD	Male	II,III,IV	+0.496	<.001	9	view →
LUAD	Female	All	+0.297	<.001	9	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

HSD17B7–CCRCC

Open the CCRCC breakdown →